A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

NCT01801904 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Panitumumab

Sponsor

National Cancer Institute, Naples

Collaborators

[object Object]